Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

1.585 -0.585 (-26.96%)
Streaming Delayed Price Updated: 11:04 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Successful Type C Meeting with the FDA
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach 
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Ring the Opening Bell at Nasdaq
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at OIS XV in San Diego
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
Via ACCESS Newswire
News headline image
OKYO Pharma to Present at the Bio International Convention
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and CEO Acquire Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
Via ACCESS Newswire
News headline image
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
From OKYO Pharma LTD
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.